
|Articles|August 1, 2003
Fluoroquinolone more effective against gram-positive bacteria
Fort Lauderdale, FL-Gatifloxacin ophthalmic solution 0.3% (Zymar, Allergan) shows clearly improved activity against commonly encountered gram-positive ocular bacteria in vitro compared with older fluoroquinolones. This fourth-generation fluoroquinolone received FDA approval in March (see related article, Ophthalmology Times, May 1 issue, Page 1).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Rayner announces Sophi Phaco System in the US
2
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
3
Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial
4
PRIMA retinal implant restores vision in patients with advanced GA
5














































